July 17 (Reuters) - Abbott (ABT.N), opens new tab warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories is rebounding from last year’s manufacturing ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...
ABBOTT PARK, Ill. and NEW YORK - Abbott (NYSE:ABT) and Flatiron Health announced today the integration of Abbott’s Precision Oncology test portfolio into OncoEMR, Flatiron’s cloud-based Electronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results